FrancophonIA/ELRC3.0 huggingface dataset:
English: High physiological uptake of gallium (68Ga) edotreotide by the pancreas uncinate process can also be observed.
Croatian: Također je moguća visoka fiziološka apsorpcija galijevog [68Ga] edotreotida u dijelu gušterače koji se naziva kukasti nastavak (procesus uncinatus).
English: The retrospective study of Kroiss et al. 2013 in 249 NET patients showed that PRRT does not significantly influence semiquantitative uptake of gallium (68Ga) edotreotide PET, except in liver metastases of patients with NET, but the study lacked histological confirmation.
Croatian: Retrospektivno ispitivanje koje su proveli Kroiss i sur. 2013. na 249 bolesnika s NET-om pokazalo je da PRRT značajno ne utječe na semikvantitativnu apsorpciju galijevog [68Ga] edotreotida pri PET-u,
English: • One vial of powder for solution for injection: 10 ml Type I glass vial closed with a bromobutyl rubber stopper and sealed with a flip-off cap. Each vial contains 40 micrograms of edotreotide.
Croatian: • Jednu bočicu praška za otopinu za injekciju: bočica od 10 ml od stakla tipa I, zatvorena bromobutilnim gumenim čepom i zabrtvljena zaštitnim zatvaračem.
English: With a 5 mL sterile syringe and a sterile needle (coated with silicone or other appropriate material able to reduce metal impurity trace - not supplied) carefully withdraw 4 mL of water for injections (not supplied) and reconstitute the powder in Vial 1.
Croatian: Sterilnom štrcaljkom od 5 ml i sterilnom iglom (presvučenom silikonom ili drugim odgovarajućim materijalom koji može smanjiti metalna onečišćenja - nije dostavljeno)
English: STATEMENT OF ACTIVE SUBSTANCE(S) One vial of powder contains 40 micrograms of edotreotide
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Svaka bočica praška sadržava 40 mikrograma edotreotida
English: monograph 2464 Gallium (68Ga) chloride solution for radiolabelling and that, in addition, is sterile and has been tested for compatibility with SomaKit TOC.
Croatian: Namijenjen je radioaktivnom obilježavanju otopinom galijevog [68Ga] klorida koja je u skladu s monografijom 2464 Europske farmakopeje Otopina galijevog [68Ga] klorida za radioaktivno obilježavanje te koja je sterilna i čija je kompatibilnost sa setom SomaKit TOC ispitana.
English: What you need to know before SomaKit TOC is used 3.
Croatian: Što morate znati prije primjene lijeka SomaKit TOC 3. Kako se SomaKit TOC primjenjuje
English: Pharmacotherapeutic group: Other diagnostic radiopharmaceuticals for tumour detection, ATC code: V09IX09.
Croatian: 5.1. Farmakodinamička svojstva Farmakoterapijska skupina: ostali dijagnostički radiofarmaceutici za otkrivanje tumora, ATK oznaka:
English: In the study of Kowalski et al. 2003 in 4 patients with GEP-NET, gallium (68Ga) edotreotide showed better patient-based detection rate (100%) than indium (111In) pentetreotide (50%).
Croatian: bolesnika s GEP-NET-om, galijev [68Ga] edotreotid pokazao je bolju stopu otkrivanja (100%) kod pojedinog bolesnika od indijevog (111In) pentetreotida (50%).
English: Gallium (68Ga) edotreotide solution is stable up to 4 hours after preparation.
Croatian: Slika 2: Postupak radioaktivnog obilježavanja pri korištenju generatora Galli Ad Otopina galijevog [68Ga] edotreotida stabilna je do 4 sata nakon pripreme.
English: (68 min), the biological half-life will have little impact on the effective half-life of the product which then would be expected to be somewhat less than 68 minutes.
Croatian: Budući da je brzina eliminacije znatno sporija nego fizikalni poluvijek galija(68Ga) (68 min), biološki poluvijek neće puno utjecati na efektivni poluvijek lijeka, koji bi očekivano iznosio nešto manje od 68
English: Osteogenic cells Skin
Croatian: Crvena koštana srž Osteogene stanice Koža
English: How SomaKit TOC is used
Croatian: Kako se SomaKit TOC primjenjuje
English: Renal/Hepatic impairment The pharmacokinetics in patients with renal or hepatic impairment has not been characterized.
Croatian: Farmakokinetika nije okarakterizirana u bolesnika s oštećenjem funkcije bubrega ili jetre.
English: No adverse reactions related to gallium (68Ga) edotreotide have been reported.
Croatian: Nisu zabilježene nuspojave galijevog [68Ga] edotreotida.
English: PET images with gallium (68Ga) edotreotide should be interpreted visually, and semiquantitative measurement of gallium (68Ga) edotreotide uptake should not be used for clinical interpretation of images.
Croatian: edotreotida potrebno je vizualno tumačiti, te pri kliničkom tumačenju slika ne bi trebalo primjenjivati semikvantitativno mjerenje apsorpcije galijevog [68Ga] edotreotida.
English: SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation Edotreotide
Croatian: SomaKit TOC 40 mikrograma set za pripravu radiofarmaceutika edotreotid
English: In the study of Lee et al. 2015 in 13 GEP-NET patients, a total of 35 positive lesions were detected in 10 patients on either gallium (68Ga) edotreotide PET/CT or indium (111In) pentetreotide
Croatian: 2015. na 13 bolesnika s GEP-NET-om, otkriveno je ukupno 35 pozitivnih tumora kod 10 bolesnika na PET/CT slici dobivenoj primjenom galijevog [68Ga] edotreotida ili SPECT/CT slici dobivenoj primjenom indijevog (111In) pentetreotida, dok u 3 bolesnika niti jednom metodom snimanja nisu prikazani pozitivni tumori.
English: Concomitant use of somatostatin analogues It is preferable to perform imaging with gallium (68Ga) edotreotide the day(s) before the next administration of a somatostatin analogue.
Croatian: Poželjno je obaviti oslikavanje galijevim [68Ga] edotreotidom dan (ili nekoliko dana) prije sljedeće primjene somatostatinskog analoga.
English: No radioactive metabolites were detected in serum within 4 hours after intravenous injection of gallium (68Ga) edotreotide.
Croatian: Eliminacija Unutar četiri sata nakon intravenske primjene galijevog [68Ga] edotreotida nisu nađeni radioaktivni metaboliti u serumu.
English: d. Scan the ITLC with a radiometric ITLC scanner e. The retention factor (Rf) specifications are as follows: Not complexed gallium (68Ga) = 0 to 0.1 gallium (68Ga) edotreotide = 0.8 to 1
Croatian: Specifikacije faktora zadržavanja (Rf) su sljedeće: [68Ga] edotreotid = 0,1 do 0,2
English: Ga) edotreotide to structures or receptors other than SSTR remains unknown.
Croatian: Nadalje, nije poznato veže li se galijev [68Ga] edotreotid in vivo na druge strukture ili receptore osim SSTR-a.
English: Figure 1.
Croatian: PRILOG III.
English: NAME OF THE MEDICINAL PRODUCT SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation
Croatian: NAZIV LIJEKA SomaKit TOC 40 mikrograma set za pripravu radiofarmaceutika
English: Interpretation of gallium (68Ga) edotreotide images and limitations of use PET images with gallium (68Ga) edotreotide reflect the presence of somatostatin receptors in the tissues.
Croatian: PET slike dobivene primjenom galijevog [68Ga] edotreotida odražavaju prisutnost somatostatinskih receptora u tkivima.
English: 01630 Saint Genis Pouilly France tel: +33 4 50 99 30 70 fax: +33 4 50 99 30 71 e-mail: info@adacap.com
Croatian: Faks: +33 4 50 99 30 71
English: • One vial of buffer: 10 ml cyclic olefin polymer vial closed with a teflon stopper and sealed with a flip-off cap. Each vial contains 1 ml of reaction buffer.
Croatian: • Jednu bočicu pufera: bočica od 10 ml od cikličkog olefinskog polimera zatvorena teflonskim čepom i zabrtvljena zaštitnim zatvaračem.
English: - if you have others medical conditions, such as high level of cortisol in the body (Cushing syndrome), inflammation, thyroid disease, other type of tumour (of pituitary gland, lung, brain, breast, immune system, thyroid, adrenal gland or others) or disease of spleen that may affect the interpretation of the images; - if you have been taking other medicines, such as somatostatin analogues and glucocorticoids, which may interact with SomaKit TOC; - if you are pregnant or believe you may be pregnant; - If you are breast-feeding.
Croatian: - ako ste uzimali druge lijekove, poput somatostatinskih analoga i glukokortikoida, koji bi mogli djelovati u interakciji s lijekom SomaKit TOC; - ako ste trudni ili mislite da biste mogli biti trudni; - ako dojite.
English: Administration of SomaKit TOC and conduct of the procedure After radiolabelling, SomaKit TOC is administered by intravenous injection.
Croatian: Nakon radioaktivnog obilježavanja Somakit TOC primjenjuje se injekcijom u venu.
English: The organs with high physiological uptake of gallium (68Ga) edotreotide include spleen, kidneys, liver, pituitary gland, thyroid gland and adrenals.
Croatian: Organi s visokom fiziološkom apsorpcijom galijevog [68Ga] edotreotida uključuju slezenu, bubrege,
English: - A glass vial with yellow flip-off cap containing a clear and colourless solution.
Croatian: - staklenu bočicu s crnim zaštitnim zatvaračem koja sadržava bijeli prašak. - staklenu bočicu sa žutim zaštitnim zatvaračem koja sadržava bistru i bezbojnu otopinu.
English: In vivo, semiquantitative correlation was not assessed between gallium (68Ga) edotreotide uptake in tumours and the density of SSTR in histopathological samples neither in GEP-NET patients nor in normal organs.
Croatian: SSTR-a u histopatološkim uzorcima nije procijenjena in vivo niti u bolesnika s GEP-NET-om niti u zdravim organima.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS POWDER VIAL
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of powder contains 40 micrograms of edotreotide.
Croatian: Svaka bočica praška sadržava 40 mikrograma edotreotida.
English: How SomaKit TOC is stored
Croatian: Kako se SomaKit TOC čuva
English: Formic acid
Croatian: Stijenka žučnog mjehura
English: Buffer
Croatian: Pufer
English: Therefore, when treating patients with somatostatin analogues, it is preferable to perform imaging with gallium (68Ga) edotreotide the day(s) preceding the next administration of a somatostatin analogue.
Croatian: Zato je pri liječenju bolesnika somatostatinskim analozima poželjno obaviti oslikavanje galijevim [68Ga]
English: Renal / Hepatic impairment
Croatian: Oštećenja funkcije bubrega / jetre
English: The activity of gallium (68Ga) edotreotide has to be measured with an activimeter immediately prior to injection.
Croatian: Neposredno prije primjene injekcije potrebno je izmjeriti aktivnost galijevog [68Ga] edotreotida mjeračem radioaktivnosti.
English: Moreover, the in vivo binding of gallium (
Croatian: Nakon intravenske injekcije galijev [
English: Elimination
Croatian: Predoziranje
English: Material
Croatian: Metoda
English: A schematic representation of the radiolabelling procedure is shown in
Croatian: Shematski prikaz postupka radioaktivnog obilježavanja prikazan je na Slici 1.
English: NAME OF THE MEDICINAL PRODUCT SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation edotreotide
Croatian: Uputa o lijeku: Informacije za korisnika SomaKit TOC 40 mikrograma set za pripravu radiofarmaceutika edotreotid
English: Refer to the Summary of Product Characteristics of the particular generator for more information.
Croatian: Za više informacija o dotičnom generatoru pogledajte sažetak opisa svojstava lijeka.
English: If you get any side effects talk to your nuclear medicine doctor.
Croatian: Ako imate pitanja, obratite se svojemu liječniku specijalistu nuklearne medicine.
English: Urinary bladder wall Uterus
Croatian: Stijenka mokraćnog mjehura
English: How SomaKit TOC is stored 6.
Croatian: Kako se SomaKit TOC čuva 6. Sadržaj pakiranja i druge informacije
English: Pancreas
Croatian: Nuspojave
English: 300 ml (20 mg/ml)
Croatian: 20 mg/ml
English: Invented name Strength Pharmaceutical Form Route of Administration
Croatian: Doza Farmaceutski oblik
English: 1 bottle + 1 cup + 1 oral syringe
Croatian: Boca (staklena) 300 ml (20 mg/ml) 1 boca + 1 čaša + 1 štrcaljka za usta
English: Bottle (glass)
Croatian: Sastav (koncentracija)
English: This summary was last updated in 11-2016.
Croatian: Ovaj sažetak je posljednji put ažuriran u 11. 2016.
English: The full EPAR for Abilify can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Abilify nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Abilify on 4 June 2004.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Abilify na snazi u Europskoj uniji od 4. lipnja 2004.
English: With regard to safety, the medicine has side effects comparable to those of other antipsychotics.
Croatian: U pogledu sigurnosti, lijek je uzrokovao nuspojave usporedive s onima drugih psihotika.
English: This is a summary of the European public assessment report (EPAR) for Abilify.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Abilify.
English: Abilify aripiprazole
Croatian: Abilify aripiprazol
English: What measures are being taken to ensure the safe and effective use of Abilify?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Abilify?
English: It can also be used for up to 12 weeks to treat manic episodes in adolescents from the age of 13 years.
Croatian: Također se do najduže 12 tjedana može koristiti za liječenje maničnih epizoda u adolescenata u dobi od 13 godina i starijih.
English: The most common side effects with the injection (occurring in up to 10 patients in 100) are sleepiness, dizziness and nausea.
Croatian: Najčešće nuspojave kod primjene injekcije (koje se javljaju u do 10 bolesnika na 100) su pospanost, vrtoglavica i mučnina.
English: The exact way it works is not known but it attaches in the brain to receptors for two substances (neurotransmitters) called dopamine and serotonin (5HT), which are believed to play a role in schizophrenia and bipolar disorder.
Croatian: Njegovo djelovanje nije točno utvrđeno, no veže se za receptore u mozgu odgovorne za dvije tvari (neurotransmitere) naziva dopamin i serotonin (5HT), za koje se smatra da utječu na shizofreniju i bipolarni poremećaj.
English: In adults, the most common side effects when taking Abilify by mouth (occurring in up to 10 patients in 100) are restlessness, difficulty sleeping, anxiety, extrapyramidal disorder (uncontrolled twitching or jerking), akathisia (a constant urge to move), tremor (shaking), dizziness, sleepiness, headache, blurred vision, dyspepsia (heartburn), vomiting, nausea (feeling sick), constipation, salivary hypersecretion (increased production of saliva), tiredness and diabetes.
Croatian: U odraslih su najčešće nuspojave lijeka Abilify uzimanog na usta (koje se javljaju u do 10 bolesnika na 100) nemir, poremećaj spavanja, uznemirenost, ekstrapiramidalni poremećaji (nekontroliran trzaji ili tikovi) akatizija (potreba za neprekidnim kretanjem), tremor (treskavica), vrtoglavica, pospanost, glavobolja, poremećaj vida, dispepsija (žgaravica), povraćanje, mučnina (slabost), konstipacija, hipersekrecija sline, umor i dijabetes.
English: Bipolar I disorder
Croatian: Bipolarni poremećaj I
English: What is Abilify and what is it used for?
Croatian: Što je Abilify i za što se koristi?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that the benefits of Abilify are greater than its risks and recommended its approval in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji stoga je odlučio da koristi od lijeka Abilify nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Why is Abilify approved?
Croatian: Zašto je Abilify odobren?
English: By attaching to these receptors, it is thought that aripiprazole helps normalise the activity of the brain, reducing psychotic or manic symptoms and preventing them from returning.
Croatian: Smatra se da aripipazol vezivanjem na te receptore pomaže pri normalizaciji moždane aktivnosti, smanjenjem psihotičnih ili maničnih simptoma te sprječavanjem njihova ponavljanja.
English: It is also available as a solution for injection into the shoulder or buttock muscle.
Croatian: Također je dostupan kao otopina za injekciju koja se daje u rame ili mišić stražnjice.
English: The side effects are similar in adolescents, but sleepiness, extrapyramidal disorder, akathisia and tiredness are very common in this group (in more than 1 in 10 adolescents).
Croatian: Nuspojave su slične u adolescenata, no pospanost, ekstrapiramidalni poremećaji, akatizija i umor vrlo su česti u ovoj dobnoj skupini (javljaju se u više od 1 na 10 adolescenata).
English: Other information about Abilify
Croatian: Ostale informacije o lijeku Abilify
English: It is not intended to provide practical advice on how to use Abilify.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Abilify.
English: Abilify is available as tablets and a liquid to be taken by mouth.
Croatian: Abilify je dostupan u obliku tableta i tekućine koje se uzimaju na usta.
English: Abilify has also been studied in 302 adolescents aged between 13 and 17, with results showing Abilify to be more effective than placebo.
Croatian: Abilify je nadalje ispitivan na 302 adolescenta u dobi od 13 do 17 godina, u kojih su rezultati pokazali da je Abilify bio djelotvorniji od placeba.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abilify have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Abilify nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Other studies showed that Abilify was more effective than placebo at preventing manic episodes in previously treated adults for up to 74 weeks, and when it was used as an add-on to existing treatment.
Croatian: Druga su ispitivanja pokazala da je Abilify djelotvorniji od placeba u suzbijanju maničnih epizoda do 74 tjedna u odraslih koji su prethodno liječeni, i kada je korišten kao dodatak postojećoj terapiji.
English: Studies showed that Abilify is effective at treating symptoms of schizophrenia using standard rating scales (such as the Positive and Negative Syndrome Scale, PANSS).
Croatian: Ispitivanja su pokazala da Abilify učinkovito liječi simptome shizofrenije korištenjem standardnih ljestvica procjene (poput ljestvice pozitivnih i negativnih simptoma - PANSS)
English: What is the risk associated with Abilify?
Croatian: Koji su rizici povezani s lijekom Abilify?
English: Abilify can only be obtained with a prescription.
Croatian: Abilify se izdaje samo na liječnički recept.
English: In bipolar I disorder, Abilify is used in adults to treat manic episodes (periods of abnormally high mood) and to prevent new ones in those who have responded to the medicine in the past.
Croatian: Kod bipolarnog poremećaja I, Abilify se koristi u odraslih za liječenje maničnih epizoda (razdoblja pretjerano dobrog raspoloženja) i za suzbijanje novih maničnih epizoda u osoba koje su u prošlosti reagirale na lijek.
English: For more information about treatment with Abilify, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Abilify pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: In another adult study, Abilify was as effective as haloperidol, another antipsychotic medicine, in preventing symptoms from returning over 1 year.
Croatian: U drugom ispitivanju na odraslima, Abilify je bio jednako učinkovit kao i drugi antipsihotik, haloperidol, u sprječavanju ponavljanja simptoma duže od godinu dana.
English: A study in 296 children and adolescents showed that Abilify was more effective than placebo at reducing the manic symptoms in patients aged 13 years and older.
Croatian: Ispitivanje na 296 djece i adolescenata pokazalo je da je Abilify djelotvorniji od placeba u smanjenju maničnih simptoma u bolesnika od 13 godina i starijih.
English: Abilify is an antipsychotic medicine for patients with schizophrenia and bipolar I disorder.
Croatian: Abilify je antipsihotik za liječenje bolesnika sa shizofrenijom i bipolarnim poremećajem.
English: For practical information about using Abilify, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Abilify bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: In addition, the injection has been shown to be effective at quickly controlling agitation or disturbing behaviour in patients with schizophrenia or bipolar I disorder.
Croatian: Nadalje, pokazalo se da je primjena injekcijom bila učinkovita za brzu kontrolu uznemirenosti ili poremećenog ponašanja u bolesnika sa shizofrenijom ili bipolarnim poremećajem I.
English: In 4 out of 5 studies in 1,900 adults, Abilify was more effective than placebo at reducing manic symptoms, with two of these studies showing that Abilify has a similar effect to haloperidol and to lithium.
Croatian: U četiri od pet ispitivanja na 1900 odraslih, Abilify je bio djelotvorniji od placeba u smanjivanju maničnih simptoma, pri čemu su dva od tri ispitivanja pokazala da Abilify ima sličan učinak haloperidolu i litiju.
English: Studies comparing Abilify to placebo or other medicines (such as haloperidol and lithium) show that Abilify is effective at reducing symptoms of schizophrenia and at treating and preventing high moods in patients with bipolar I disorder.
Croatian: Ispitivanja u kojima je Abilify uspoređen s placebom ili drugim lijekovima (poput haloperidola i litija) pokazala su da je Abilify djelotvoran u smanjenju simptoma shizofrenije te u liječenju hiperaktivnog ponašanja u bolesnika s bipolarnim poremećajem I.
English: Finally, a study in 291 patients treated by injection for agitation and disturbed behaviour showed that improvement with Abilify was greater after 2 hours than with placebo and similar to that with lorazepam (another medicine for treating agitation).
Croatian: Konačno, ispitivanje na 291 bolesniku liječenih injekcijom za uznemirenost i poremećeno ponašanje pokazalo je veće poboljšanje simptoma s lijekom Abilify nakon dva sata nego s placebom, pri čemu je poboljšanje bilo slično onom s lorazepamom (drugim lijekom protiv uznemirenosti).
English: In studies of 1,203 adults, Abilify was more effective than placebo (a dummy treatment) at reducing symptoms.
Croatian: U ispitivanju na 1203 odrasle osobe, Abilify je bio djelotvorniji od placeba (prividnog liječenja) pri smanjenju simptoma.
English: What benefits of Abilify have been shown in studies?
Croatian: Koje su koristi lijeka Abilify utvrđene u ispitivanjima?
English: How is Abilify used?
Croatian: Kako se Abilify koristi?
English: A study in 544 patients treated by injection for agitation and disturbed behaviour showed that improvement with Abilify over 24 hours was greater than with placebo and similar to that with haloperidol.
Croatian: Ispitivanje na 544 bolesnika liječenih injekcijom za uznemirenost i poremećeno ponašanje pokazalo je veće poboljšanje simptoma tijekom 24 sata nego s placebom, pri čemu je poboljšanje bilo slično onom s haloperidolom.
English: Studies in bipolar I disorder showed that Abilify is effective at treating manic episodes using standard measurements such as the Young-Mania Rating Scale (YMRS) scale.
Croatian: I pokazala su da je Abilify učinkovit u liječenju maničnih epizoda korištenjem standardnih mjerila poput ljestvice procjene stupnja manije u mladih (YMRS).
English: The injection is used only for quickly controlling agitation or disturbed behaviour in patients with schizophrenia or bipolar I disorder.
Croatian: Injekcija se koristi samo za brzu kontrolu uznemirenosti ili poremećenog ponašanja u bolesnika sa shizofrenijom ili bipolarnim poremećajem I. Informacije o doziranju i prilagodbi doza nalaze se u uputi o lijeku.
English: The active substance in Abilify is aripiprazole.
Croatian: Djelatna tvar lijeka Abilify je aripiprazol.